SBV Journal of Basic, Clinical and Applied Health Science

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  6 (2023)
Volume  5 (2022)
Volume  4 (2021)
Volume  3 (2020)
Volume  2 (2019)
Volume  1 (2018)
Related articles

VOLUME 6 , ISSUE 2 ( April-June, 2023 ) > List of Articles

REVIEW ARTICLE

Potassium-competitive Acid Blocker: A Newer Target in the Treatment of Acid Peptic Disorder

Navinraja Komal Veererathinakumar, Vimala Ananthy, R Sudar Codi, K Manimekalai

Keywords : Acid peptic disorders, H+K+-ATPase (proton pump), Proton-pump inhibitors, Potassium-competitive acid blocker, Vonoprazan

Citation Information : Veererathinakumar NK, Ananthy V, Codi RS, Manimekalai K. Potassium-competitive Acid Blocker: A Newer Target in the Treatment of Acid Peptic Disorder. 2023; 6 (2):33-38.

DOI: 10.5005/jp-journals-10082-03182

License: CC BY-NC 4.0

Published Online: 13-04-2023

Copyright Statement:  Copyright © 2023; The Author(s).


Abstract

Acid peptic disorders are a group of disorders that include gastroesophageal reflux disease, gastric ulcer, and duodenal ulcer. The most common causes are nonsteroidal anti-inflammatory drugs (NSAIDs) and Helicobacter pylori infection. If not treated adequately, it may lead to life-threatening complications like gastrointestinal bleeding and intestinal perforation. H+K+-ATPase enzyme in parietal cells is involved in the final step of gastric acid secretion through a conformational change from E1 to E2 form. Proton-pump inhibitors (PPIs) are commonly used drugs for the treatment of acid peptic disorders. Proton-pump inhibitors have some limitations such as irreversible inhibition, it is a prodrug. Continuous attempts are made to develop newer targets that overcome these limitations of PPIs in treating acid peptic disorders. Vonoprazan, a novel potassium-competitive acid blocker (P-CAB) approved by the FDA for H. pylori infection in combination with antibiotics, could be a potential alternative to PPI in the management of acid peptic disorders. This review mainly highlights the pharmacology of Vonoprazan.

HTML PDF Share
  1. Sanders SW. Pathogenesis and treatment of acid peptic disorders: Comparison of proton pump inhibitors with other antiulcer agents. Clin Ther 1996;18(1):2–34. DOI: 10.1016/s0149-2918(96)80175-5.
  2. Mejia A, Kraft WK. Acid peptic disease: Pharmacological approach to treatment. Expert Rev Clin Pharmacol 2009;2(3):295–314. DOI: 10.1586/ecp.09.8.
  3. Kuna L, Jakab J, Smolic R, Raguz-Lucic N, Vcev A, Smolic M. Peptic ulcer disease: A brief review of conventional therapy and herbal treatment options. J Clin Med 2019;8(2):179. DOI: 10.3390/jcm8020179.
  4. Malik TF, Gnanapandithan K, Singh K. Peptic ulcer disease. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK534792/
  5. Salari N, Darvishi N, Shohaimi S, Bartina Y, Ahmadipanah M, Salari HR, et al. The global prevalence of peptic ulcer in the world: A systematic review and meta-analysis. Indian J Surg 2021(9337):1–9. DOI: 10.1007/s12262-021-03189-z.
  6. Nirwan JS, Hasan SS, Babar ZU, Conway RR, Ghori MU. Global prevalence and risk factors of gastro-oesophageal reflux disease (GORD): Systematic review with meta-analysis. Sci Rep 2020;10(1):5814. DOI: 10.1038/s41598-020-62795-1.
  7. Bhatia SJ, Makharia GK, Abraham P, Bhat N, Kumar A, Reddy DN, et al. Indian consensus on gastroesophageal reflux disease in adults: A position statement of the Indian society of Gastroenterology. Indian J Gastroenterol 2019;38(5):411–440. DOI: 10.1007/s12664-019-00979-y.
  8. Varela-Chinchilla CD, Segura N. Histology, parietal cells. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2022. Available from: https://www.ncbi.nlm.cih.goc/books/NBK547758/
  9. Sachs G, Shin JM, Vagin O, Lambrecht N, Yakubov L, Munson K. The gastric H,K-ATPase as a drug target: Past, present, and future. J Clin Gastroenterol 2007;41(2):S226–S242. DOI: 10.1097/MCG.0b013e31803233b7
  10. Yao X, Forte JG. Cell biology of acid secretion by the parietal cell. Annu Rev Physiol 2003;65:103–131. DOI: 10.1146/annurev.physiol.65.072302.114200.
  11. Arin RM, Gorostidi A, Navarro-Imaz H, Rueda Y, Fresnedo O, Ochoa B. Adenosine: Direct and indirect actions on gastric acid secretion. Front Physiol 2017;8:737:155–189. DOI: 10.3389/fphys.2017.00737.
  12. Shin JM, Kim N. Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. J Neurogastroenterol Motil 2013;19(1):25–35. DOI: 10.5056/jnm.2013.19.1.25.
  13. Hersey SJ, Sachs G. Gastric acid secretion. Physiol Rev 1995;75(1):155–189. DOI: 10.1152/physrev.1995.75.1.155.
  14. Jenkins H, Sakurai Y, Nishimura A, Okamoto H, Hibberd M, Jenkins R, et al. Randomised clinical trial: Safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan). A novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther 2015;41(7):636–648. DOI: 10.1111/apt.13121.
  15. Matsukawa J, Hori Y, Nishida H, Kajino M, Inatomi N. A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands. Biochem Pharmacol 2011;81(9):1145–1151. DOI: 10.1016/j.bcp.2011.02.009.
  16. Sakurai Y, Mori Y, Okamoto H, Nishimura A, Komura E, Araki T, et al. Acid inhibitory effects of vonoprazan 20 mg compared with esmoprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects – a randomized open-label cross-over study. Aliment Pharmacol Ther 2015;42(6):719–730. DOI: 10.1111/apt.13325.
  17. Parsons ME, Keeling DJ. Novel approach to the pharmacological blockade of gastric acid secretion. Expert Opin Investig Drugs 2005;14(4):411–421. DOI: 10.1517/13543784.14.4.411.
  18. Wallmark B, Briving C, Fryklund J, Munson K, Jackson R, Mendelein J, et al. Inhibition of gastric H+,K+-ATPase and acid secretion by SCH 28080, a substituted pridyl(1,2a)imidazole. J Biol Chem 1987;262(5):2077–2084. PMID: 3029064.
  19. Shin JM, Inatomi N, Munson K, Strugatsky D, Tokhtaeva E, Vagin O, et al. Characterization of novel potassium-competitive acid blocker of the gastric H,K-ATPase, 1-[5-(2-Fluorophenyl)-1-(pyridine-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438). J Pharmacol Exp Ther 2011;339(2):412–420. DOI: 10.1124/jpet.111.185314.
  20. Hori Y, Matsukawa J, Takeuchi T, Nishida H, Kajino M, Inatomi N. A study comparing the antisecretory effect of TAK-438, a novel potassium-competitive acid blocker, with lansoprazole in animals. J Pharmacol Exp Ther 2011;337(3):797–804. DOI: 10.1124/jpet.111.179556.
  21. Otake K, Sakurai Y, Nishida H, Fukui H, Tagawa Y, Yamasaki H, et al. Characteristics of the novel potassium-competitive acid blocker vonoprazan fumarate (TAK-438). Adv Ther 2016;33(7):1140–1157. DOI: 10.1007/s12325-016-0345-2.
  22. Scot DR, Munson KB, Marcus EA, Lambrecht NW, Sachs G. The binding selectivity of vonoprazan (TAK-438) to the gastric H+,K+-ATPase. Aliment Pharmacol Ther 2015;42(11–12):1315–1326. DOI: 10.1111/apt.13414.
  23. Yamasaki H, Kawaguchi N, Nonaka M, Takahashi J, Morohashi A, Hirabayashi H, et al. In vitro metabolism of TAK-438, vonoprazan fumarate, a novel potassium-competitive acid blocker. Xenobiotica 2017;47(12):1027–1034. DOI: 10.1080/00498254.2016.1203505.
  24. Yoneyama T, Teshima K, Jinno F, Kondo T, Asahi S. A validated simultaneous quantification method for vonoprazan (TAK-438F) and its 4 metabolites in human plasma by the liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed 2016;1015–1016:42–49. DOI: 10.1016/j.jchromb.2016.01.051.
  25. Sakurai Y, Nishimura A, Kennedy G, Hibberd M, Jenkins R, Okamoto H, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single rising TAK-438 (vonoprazan) doses in healthy male Japanese/non-Japanese subjects. Clin Transl Gastroenterol 2015;6(6):e94. DOI: 10.1038/ctg.2015.18.
  26. Jung YS, Kim EH, Park CH. Systematic review with meta-analysis: The efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication. Ailment Pharmacol Ther 2017;46(2):106–114. DOI: 10.1111/apt.14130.
  27. Kamiya K, Nishio E, Horio A, Tokura Y. Erythema multiforme caused by triple therapy with amoxicillin, clarithromycin and vonoprazan for Helicobacter pylori. J Dermatol 2016;43(3):340–341. DOI: 10.1111/1346-8138.13187.
  28. Suzuki S, Gotoda T, Kusano C, Iwatsuka K, Moriyama M. The efficacy and tolerability of a triple therapy containing a potassium-competitive acid blocker compared with a 7-day PPI-based low-dose clarithromycin triple therapy. Am J Gastroenterol 2016;111(7):949–956. DOI: 10.1038/ajg.2016.182.
  29. Suzuki T, Kagami T, Uotani T, Yamade M, Hamaya Y, Iwaizumi M. Comparison of effect of an increased dosage of vonoprazan versus vonoprazan plus lafutidine on gastric acid inhibition and serum gastrin. Eur J Clin Pharmacol 2018;74(1):45–52. DOI: 10.1007/s00228-017-2324-1.
  30. Tanaka K, Fujiya M, Sakatani A, Fujibayashi S, Nomura Y, Ueno N. Second-line therapy for Helicobacter pylori eradication causing antibiotic-associated hemorrhagic colitis. Ann Clin Microbiol Antimicrob 2017;16(1):54. DOI: 10.1186/s12941-017-0230-0.
  31. Nishimura N, Mizuno M, Matsueda K. Gastroduodenal intussusceptions due to vonoprazan-induced gastric polyps. Intern Med 2022;61(8):1305–1306. DOI: 10.2169/internalmedicine.8235-21; Shin JM, Munson K, Vagin O, Sachs G. The gastric HK-ATPase: Structure, function and inhibition. Eur J Physiol 2009;457(3):609–622. DOI: 10.1007/s00424-008-0495-4.
  32. Ishida M, Tsuchiya M, Naito J, Kawazoe H, Watanabe D, Nonaka Y, et al. Vonoprazan-associated nephrotoxicity: Extensive real-world evidence from spontaneous adverse drug reaction reports. Kidney Int 2022;102(3):666–668. DOI: 10.1016/j.kint.2022.06.007.
  33. Chey WD, Megraud F, Laine L, Lopez LJ, Hunt B, Howden CW. Vonoprazan triple and dual therapy for Helicobacter pylori infection in the United States and Europe: Randomized clinical trial. Gastroenterology 2022;163(3):608–619. DOI: 10.1053/j.gastro.2022.05.055.
  34. Ashida K, Sakurai Y, Hori T, Kudou K, Nishimura A, Hiramatsu N, et al. Randomized clinical trial: Vonoprazan, a novel potassium acid blocker vs. lansoprazole for the healing of erosive oesophagitis. Ailment Pharmacol Ther 2016;43(2):240–251. DOI: 10.1111/apt.13461.
  35. Kagawa T, Iwamuro M, Ishikawa S, Ishida M, Kuraoka S, Sasaki K, et al. Vonoprazan prevents bleeding from endoscopic submucosal dissection-induced gastric ulcers. Ailment Pharmacol Ther 2016;44(6):583–591. DOI: 10.1111/apt.13747.
  36. Hoshino S, Kawami N, Takenouchi N, Umezawa M, Hanada Y, Hoshikawa Y, et al. Efficacy of vonoprazan for proton pump inhibitor-resistant reflux esophagitis. Digestion 2017;95(2):156–161. DOI: 10.1159/000456072.
  37. Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: A phase III, randomized, double-blind study. Gut 2016;65(9):1439–1446. DOI: 10.1136/gutjnl-2015-311304.
  38. Ashida K, Sakurai Y, Nishimura A, Kudou K, Hiramatsu N, Umegaki E, et al. Randomised clinical trial: A dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker vs. lansoprazole for the treatment of erosive oesophagitis. Ailment Pharmacol Ther 2015;42(6):685–695. DOI: 10.1111/apt.13331.
  39. Iwakiri K, Sakurai Y, Shino M, Okamoto H, Kudou K, Nishimura A, et al. A randomized, double-blind study to evaluate the acid-inhibitory effect of vonoprazan (20 mg and 40 mg) in patients with proton-pump inhibitor-resistant erosive esophagitis. Therap Adv Gastroenterol 2017;10(6):439–451. DOI: 10.1177/1756283X17705329.
  40. Takahashi K, Sato Y, Kohisa J, Watanabe J, Sato H, Mizuno K, et al. Vonoprazan 20 mg vs lansoprazole 30 mg for endoscopic submucosal dissection-induced gastric ulcers. World J Gastrointest Endosc 2016;8(19):716–722. DOI: 10.4253/wjge.v8.i19.716.
  41. Kinoshita Y, Sakurai Y, Shino M, Kudou K, Nishimura A, Miyagi T, et al. Evaluation of efficacy and safety of vonoprazan in patient with nonerosive gastroesophageal reflux disease: A phase III, randomized, double-blind, placebo-controlled, multicentre study. Curr Ther Rex Clin Exp 2016;81–82:1–7. DOI: 10.1016/j.curtheres.2016.12.001.
  42. Yang E, Kim S, Kim B, Kim Y, Park SS, Song GS, et al. Night-time gastric acid suppression by tegoprazan compared to vonoprazan or esmoprazole. Br J Clin Pharmacol 2022;88(7):3288–3296. DOI: 10.1111/bcp.15268.
  43. Kim DK, Lee K-H, Kim SJ, Kim S-J, Lee SJ, Park CH, et al. Effects of tegoprazan, a novel potassium-competitive acid blocker, on rat models of gastric acid-related disease. J Pharmacol Exp Ther 2019;369(3):318–327. DOI: 10.1124/jpet.118.254904.
  44. Han S, Choi HY, Kim YH, Nam JY, Kim B, Song GS, et al. Randomised clinical trial: Safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of tegoprazan (CJ-12420), a novel potassium-competitive acid blocker, in healthy male subjects. Ailment Pharmacol Ther 2019;50(7):751–759. DOI: 10.1111/apt.15438.
  45. Cho YK, Choi MG, Choi SC, Lee KM, Kim TO, Park SH, et al. Randomised clinical trial: Tegoprazan, a novel potassium-competitive acid blocker, or lansoprazole in the treatment of gastric ulcer. Ailment Pharmacol Ther 2020;52(5):789–797. DOI: 10.1111/apt.15865.
  46. Son M, Park IS, Kim S, Ma HW, Kim JH, Kim TI, et al. Novel potassium-competitive acid blocker, tegoprazan, protects against colitis by improving gut barrier function. Front Immunol 2022;13:870817. DOI: 10.3389/fimmu.2022.870817.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.